

Wet Age-Related Macular Degeneration (Wet-AMD) - Pipeline Insight, 2021

<https://marketpublishers.com/r/W7E02CCC19ECEN.html>

Date: May 2021

Pages: 190

Price: US\$ 2,500.00 (Single User License)

ID: W7E02CCC19ECEN

Abstracts

This report can be delivered to the clients within 72 Hours

DelveInsight's, "Wet Age-Related Macular Degeneration (Wet-AMD) - Pipeline Insight, 2021," report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Wet Age-Related Macular Degeneration (Wet-AMD) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Wet Age-Related Macular Degeneration (Wet-AMD) Understanding

Wet Age-Related Macular Degeneration (Wet-AMD): Overview

Age-related macular degeneration (AMD) is a multifactorial ocular disease that affects the maculae due to late-onset progressive neurodegeneration and dysfunction of photoreceptors and retinal pigment epithelium (RPE). Majorly, there are two types of AMD: dry (atrophic) and wet (neovascular or exudative). Most AMD starts as the dry type, and in 10–20% of individuals, it progresses to the wet type. Wet AMD is less common but more severe than the dry type.

Wet AMD, also known as neovascular AMD or exudative AMD, is a form of retinal

degeneration in which abnormal choroidal neovascularization occurs under the retina and macula lutea. Because these new blood vessels are abnormal, they tend to break, bleed, and leak fluid, damaging the macula and causing it to lift up and pull away from its base. This can result in a rapid and severe loss of central vision.

The complaints of a patient with wet AMD may vary from metamorphopsia, central or paracentral scotoma, to a sudden, nonspecific reduction in central vision. Common symptoms of wet AMD include: Distortion of straight lines (metamorphopsia), a blind spot or hole in one's vision (scotoma), difficulty with adaptation to the dark.

Age-related macular degeneration is defined by fundus examination, but the diagnosis of AMD is typically based on age, clinical findings through various tests like Color fundus photography, Fluorescein angiography and/or Optical coherence tomography. Color photography and fluorescein angiography are done when findings suggest wet AMD. A simple test for daily monitoring of vision in patients with AMD is the Amsler grid. Anti-VEGF medications are the most effective and most common treatment for wet AMD. Patients with unilateral wAMD should take the daily nutritional supplements that are recommended for dry AMD to reduce the risk of AMD-induced vision loss in the other eye.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Wet Age-Related Macular Degeneration (Wet-AMD) R&D. The therapies under development are focused on novel approaches for Wet Age-Related Macular Degeneration (Wet-AMD).

Wet Age-Related Macular Degeneration (Wet-AMD) Emerging Drugs Chapters

This segment of the Wet Age-Related Macular Degeneration (Wet-AMD) report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Wet Age-Related Macular Degeneration (Wet-AMD) Emerging Drugs

SOK583A1: Sandoz

Aflibercept binds and inhibits ocular VEGF-A and prevents abnormal growth of blood vessels in the choroid, impacting visual function. It improves visual acuity in patients with neovascular retinal diseases like nAMD, DME, and RVO. SOK583A1 is a biosimilar of Aflibercept (Eylea).

It is currently in the Phase III stage of development for the treatment of wAMD and is being developed by Sandoz. In May 2021, Sandoz announced progress in the late-stage clinical development program for its proposed biosimilar aflibercept. Sandoz will begin enrolling the first patient in MYLIGHT—a clinical Phase III confirmatory efficacy and safety study.

SB15: Samsung Bioepis

SB15 is being developed as a biosimilar to the reference product Eylea (aflibercept)—an anti-VEGF drug.

It is currently in the Phase III stage of development for the treatment of wAMD and is being developed by Samsung Bioepis. Samsung Bioepis announced in November 2019 that it entered into a new commercialization agreement with Biogen for two ophthalmology biosimilar candidates, SB11 (ranibizumab) and SB15 (aflibercept), in the US, Canada, Europe, Japan, and Australia.

Further product details are provided in the repor

Wet Age-Related Macular Degeneration (Wet-AMD): Therapeutic Assessment

This segment of the report provides insights about the different Wet Age-Related Macular Degeneration (Wet-AMD) drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Wet Age-Related Macular Degeneration (Wet-AMD)

There are approx. 70+ key companies which are developing the Wet Age-Related Macular Degeneration (Wet-AMD). The companies which have their Wet Age-Related Macular Degeneration (Wet-AMD) drug candidates in the most advanced stage, i.e.

Phase III include, Sandoz.

Phases

DelveInsight's report covers around 70+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Wet Age-Related Macular Degeneration (Wet-AMD) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Wet Age-Related Macular Degeneration (Wet-AMD): Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Wet Age-Related Macular Degeneration (Wet-AMD) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Wet Age-Related Macular Degeneration (Wet-AMD) drugs.

Wet Age-Related Macular Degeneration (Wet-AMD) Report Insights

Wet Age-Related Macular Degeneration (Wet-AMD) Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

Wet Age-Related Macular Degeneration (Wet-AMD) Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

How many companies are developing Wet Age-Related Macular Degeneration (Wet-AMD) drugs?

How many Wet Age-Related Macular Degeneration (Wet-AMD) drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Wet Age-Related Macular Degeneration (Wet-AMD)?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Wet Age-Related Macular Degeneration (Wet-AMD) therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Wet Age-Related Macular Degeneration (Wet-AMD) and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Sandoz

Sam Chun Dang Pharm

Samsung Bioepis

Opthea Limited

Luye Pharma

Shanghai Henlius Biotech

Generium Pharmaceuticals

Bioeq GmbH

Roche

Chong Kun Dang Pharmaceutical

Outlook Therapeutics

Kodiak Sciences

Amgen

Qilu Pharmaceuticals

Xbrane Biopharma

Regenxbio

Formycon

Dobecure

Gemini Therapeutics

Isarna Therapeutics

AngioLab Inc

Alkahest

Tyrogenex

IVERIC bio (formerly Ophthotech Corporation)

Tasly Pharmaceutical Group

Ribomic

Innovent Biologics

Gemini Therapeutics

GrayBug Vision

Curacle

Quark Pharmaceuticals

Bio-Thera Solutions

RemeGen

Sinocelltech

PanOptica

Clearside Biomedical

AsclepiX Therapeutics

Feramda

AiViva BioPharma

Unity Biotechnology

Kyowa Kirin

Ocular Therapeutix

Janssen Research & Development

Huabo Biopharm

EyePoint Pharmaceuticals

Shanghai Biomabs Pharmaceutical

Ashvattha Therapeutics

Samjin Pharm

Akari Therapeutics

EyevenSys

PharmAbcine

Neurophth Therapeutics

Ocugen

Key Products

SOK583A1

SCD411

SB15

OPT-302

LY09004

HLX04-O

GNR-067

FYB203

Faricimab

CKD-701

ONS-5010

KSI-301

ABP 938

BCD 300

Xlucane

RGX-314

FYB201

Etamsylate

GEM-103

ISTH0036

ALS-L1023

AKST4290

Vorolanib (X-82)

Zimura

Sanhuangjingshimingwan

RBM-007

IBI302

GEM103

GB-102

CU03

PF-04523655

BAT5906

RC 28 E

SCT510A

PAN 90806

CLS-AX

AXT107

AS101

AIV007

UBX1325

KHK4951

OTX-TKI

AAVCAGsCD59

HB002.1M

EYP-1901

CMAB818

D-4517

SJP1803/1804

Nomacopan

EYS609

EYS809

PMC-309

PMC-403

NFS-10

OCU 200

Contents

Introduction

Executive Summary

Wet Age-Related Macular Degeneration (Wet-AMD): Overview

Structure

Mechanism of Action

Pipeline Therapeutics

Comparative Analysis

Therapeutic Assessment

Assessment by Product Type

Assessment by Stage and Product Type

Assessment by Route of Administration

Assessment by Stage and Route of Administration

Assessment by Molecule Type

Assessment by Stage and Molecule Type

Wet Age-Related Macular Degeneration (Wet-AMD)– DelveInsight's Analytical Perspective

In-depth Commercial Assessment

Wet Age-Related Macular Degeneration (Wet-AMD) companies' collaborations, Licensing, Acquisition -Deal Value Trends

Wet Age-Related Macular Degeneration (Wet-AMD) Collaboration Deals

Company-Company Collaborations (Licensing / Partnering) Analysis

Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

Comparative Analysis

SOK583A1: Sandoz

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

Comparative Analysis

ISTH0036: Isarna Therapeutics

Product Description

Research and Development

Product Development Activities

Drug profiles in the detailed report.....

Early Stage Products (Phase I)

- Comparative Analysis
- UBX1325: Unity Biotechnology
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Preclinical and Discovery Stage Products
 - Comparative Analysis
- EYS809: Eyeevensys
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report.....
- Inactive Products
 - Comparative Analysis
- Wet Age-Related Macular Degeneration (Wet-AMD) Key Companies
- Wet Age-Related Macular Degeneration (Wet-AMD) Key Products
- Wet Age-Related Macular Degeneration (Wet-AMD)- Unmet Needs
- Wet Age-Related Macular Degeneration (Wet-AMD)- Market Drivers and Barriers
- Wet Age-Related Macular Degeneration (Wet-AMD)- Future Perspectives and Conclusion
- Wet Age-Related Macular Degeneration (Wet-AMD) Analyst Views
- Wet Age-Related Macular Degeneration (Wet-AMD) Key Companies
- Appendix

List Of Tables

LIST OF TABLES

Table 1 Total Products for Wet Age-Related Macular Degeneration (Wet-AMD)

Table 2 Late Stage Products

Table 3 Mid Stage Products

Table 4 Early Stage Products

Table 5 Pre-clinical & Discovery Stage Products

Table 6 Assessment by Product Type

Table 7 Assessment by Stage and Product Type

Table 8 Assessment by Route of Administration

Table 9 Assessment by Stage and Route of Administration

Table 10 Assessment by Molecule Type

Table 11 Assessment by Stage and Molecule Type

Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

Figure 1 Total Products for Wet Age-Related Macular Degeneration (Wet-AMD)

Figure 2 Late Stage Products

Figure 3 Mid Stage Products

Figure 4 Early Stage Products

Figure 5 Preclinical and Discovery Stage Products

Figure 6 Assessment by Product Type

Figure 7 Assessment by Stage and Product Type

Figure 8 Assessment by Route of Administration

Figure 9 Assessment by Stage and Route of Administration

Figure 10 Assessment by Molecule Type

Figure 11 Assessment by Stage and Molecule Type

Figure 12 Inactive Products

I would like to order

Product name: Wet Age-Related Macular Degeneration (Wet-AMD) - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/W7E02CCC19ECEN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/W7E02CCC19ECEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970